Hong Kong Stocks Surge as TSLP Antibody Therapy Phase I Trial Results Published

Stock News15:06

Significant gains were observed for SKB BIO-B (06990) and HBM HOLDINGS-B (02142) during afternoon trading. At the time of writing, SKB BIO-B had risen by 7.34% to HK$426.8, while HBM HOLDINGS-B increased by 4.65% to HK$11.7. The movement follows an announcement on March 23 that the initial human Phase I clinical trial results for HBM9378 have been published online in the peer-reviewed journal Drug Design, Development and Therapy. The favorable safety profile and extended half-life observed in the study support further evaluation of the therapy for severe immune diseases. Public information indicates that HBM9378 was jointly developed by HBM HOLDINGS-B and SKB BIO-B, with both companies sharing global rights. In January 2025, HBM HOLDINGS-B and SKB BIO-B entered into a strategic collaboration with Windward Bio, granting the latter exclusive rights to research, develop, manufacture, and commercialize the antibody globally, excluding Greater China and certain Southeast and West Asian countries.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117782838?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 15:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117782838","market":"us","top_or_hot":-1,"title":"Hong Kong Stocks Surge as TSLP Antibody Therapy Phase I Trial Results Published","media":"Stock News","content":"<p>Significant gains were observed for SKB BIO-B (06990) and HBM HOLDINGS-B (02142) during afternoon trading. At the time of writing, SKB BIO-B had risen by 7.34% to HK$426.8, while HBM HOLDINGS-B increased by 4.65% to HK$11.7. The movement follows an announcement on March 23 that the initial human Phase I clinical trial results for HBM9378 have been published online in the peer-reviewed journal Drug Design, Development and Therapy. The favorable safety profile and extended half-life observed in the study support further evaluation of the therapy for severe immune diseases. Public information indicates that HBM9378 was jointly developed by HBM HOLDINGS-B and SKB BIO-B, with both companies sharing global rights. In January 2025, HBM HOLDINGS-B and SKB BIO-B entered into a strategic collaboration with Windward Bio, granting the latter exclusive rights to research, develop, manufacture, and commercialize the antibody globally, excluding Greater China and certain Southeast and West Asian countries.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Surge as TSLP Antibody Therapy Phase I Trial Results Published</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Surge as TSLP Antibody Therapy Phase I Trial Results Published\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-24 15:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Significant gains were observed for SKB BIO-B (06990) and HBM HOLDINGS-B (02142) during afternoon trading. At the time of writing, SKB BIO-B had risen by 7.34% to HK$426.8, while HBM HOLDINGS-B increased by 4.65% to HK$11.7. The movement follows an announcement on March 23 that the initial human Phase I clinical trial results for HBM9378 have been published online in the peer-reviewed journal Drug Design, Development and Therapy. The favorable safety profile and extended half-life observed in the study support further evaluation of the therapy for severe immune diseases. Public information indicates that HBM9378 was jointly developed by HBM HOLDINGS-B and SKB BIO-B, with both companies sharing global rights. In January 2025, HBM HOLDINGS-B and SKB BIO-B entered into a strategic collaboration with Windward Bio, granting the latter exclusive rights to research, develop, manufacture, and commercialize the antibody globally, excluding Greater China and certain Southeast and West Asian countries.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0196878994.USD","symbol_name":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","start_time":0,"source_url":"","article_id":"1117782838","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117782838","pubTimestamp":1774335978,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Significant gains were observed for SKB BIO-B (06990) and HBM HOLDINGS-B (02142) during afternoon trading. At the time of writing, SKB BIO-B had risen by 7.34% to HK$426.8, while HBM HOLDINGS-B...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","06990":"科伦博泰生物-B","BK1583":"高瓴概念","BK1161":"生物科技","BK4588":"碎股","02142":"和铂医药-B","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK1574":"生物医药B类股"},"translate_title":"TSLP抗体疗法I期试验结果出炉港股大涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"06990":1,"02142":1},"content_text":"Significant gains were observed for SKB BIO-B (06990) and HBM HOLDINGS-B (02142) during afternoon trading. At the time of writing, SKB BIO-B had risen by 7.34% to HK$426.8, while HBM HOLDINGS-B increased by 4.65% to HK$11.7. The movement follows an announcement on March 23 that the initial human Phase I clinical trial results for HBM9378 have been published online in the peer-reviewed journal Drug Design, Development and Therapy. The favorable safety profile and extended half-life observed in the study support further evaluation of the therapy for severe immune diseases. Public information indicates that HBM9378 was jointly developed by HBM HOLDINGS-B and SKB BIO-B, with both companies sharing global rights. In January 2025, HBM HOLDINGS-B and SKB BIO-B entered into a strategic collaboration with Windward Bio, granting the latter exclusive rights to research, develop, manufacture, and commercialize the antibody globally, excluding Greater China and certain Southeast and West Asian countries.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117782838","isCrawlerRequest":true}